| P50 | author | Han-Chung Wu | Q90443915 |
| P2093 | author name string | I-Ju Liu | |
| | Yu-Chyi Hwang | |
| | Ruei-Min Lu | |
| | Chi-Chiu Lee | |
| | Hsin-Jung Li | |
| | Han-Zen Tsai | |
| P2860 | cites work | Chimeric Antigen Receptor Therapy | Q89419402 |
| | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Q90009464 |
| | Necitumumab for the treatment of advanced non-small-cell lung cancer | Q90009552 |
| | Antibodies to watch in 2019 | Q90270674 |
| | Human Monoclonal Antibodies: The Benefits of Humanization | Q90420157 |
| | Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience | Q90676345 |
| | Emapalumab: First Global Approval | Q90954538 |
| | Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity | Q92060266 |
| | Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections | Q92483657 |
| | Bispecific antibodies: a mechanistic review of the pipeline | Q92596473 |
| | First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment | Q92638078 |
| | Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases | Q94707047 |
| | Assembly of combinatorial antibody libraries on phage surfaces: the gene III site | Q24562659 |
| | A humanized antibody that binds to the interleukin 2 receptor | Q24600912 |
| | The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 |
| | Rapid cloning of high-affinity human monoclonal antibodies against influenza virus | Q24644672 |
| | Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 | Q24675216 |
| | Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach | Q24814395 |
| | Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures | Q26700070 |
| | Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 |
| | Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses | Q26998642 |
| | Drugs derived from phage display: from candidate identification to clinical practice | Q27007101 |
| | Human antibody production in transgenic animals | Q27023477 |
| | Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528 | Q27648835 |
| | An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies | Q27685248 |
| | Nivolumab plus ipilimumab in advanced melanoma | Q27852310 |
| | PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. | Q27853379 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Radioimmunotherapy of human tumours | Q28088825 |
| | The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS | Q28181573 |
| | The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford | Q28203956 |
| | Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer | Q28248065 |
| | Raxibacumab for the treatment of inhalational anthrax | Q28251284 |
| | Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study | Q28257337 |
| | Replacing the complementarity-determining regions in a human antibody with those from a mouse | Q28303497 |
| | High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region | Q28709119 |
| | Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? | Q28728956 |
| | Tabhu: tools for antibody humanization | Q29048195 |
| | Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface | Q29616401 |
| | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 |
| | Predominant autoantibody production by early human B cell precursors | Q29619656 |
| | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 |
| | Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. | Q30373175 |
| | Antibody humanization by structure-based computational protein design. | Q30377654 |
| | Human 4F5 single-chain Fv antibody recognizing a conserved HA1 epitope has broad neutralizing potency against H5N1 influenza A viruses of different clades | Q30430625 |
| | Toward selection of internalizing antibodies from phage libraries | Q30650054 |
| | A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies | Q30717070 |
| | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 |
| | Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine | Q35548062 |
| | Selection of cell-type specific antibodies on tissue-sections using phage display | Q35586630 |
| | Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses | Q35660595 |
| | Phage and Yeast Display | Q35672233 |
| | Strategies to guide the antibody affinity maturation process | Q35685300 |
| | Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sections. | Q35747795 |
| | Building better monoclonal antibody-based therapeutics. | Q35817552 |
| | Advancement and applications of peptide phage display technology in biomedical science | Q35898339 |
| | A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins | Q35936475 |
| | Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization | Q36007463 |
| | A common glycan structure on immunoglobulin G for enhancement of effector functions | Q36008257 |
| | Combinatorial antibody libraries: new advances, new immunological insights | Q36067103 |
| | abYsis: Integrated Antibody Sequence and Structure-Management, Analysis, and Prediction | Q36113473 |
| | Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. | Q36147353 |
| | Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema | Q36326043 |
| | Epstein-Barr virus susceptibility of normal human B lymphocyte populations | Q36348358 |
| | Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study | Q36362219 |
| | B Cells, Antibodies, and More | Q36432935 |
| | Antibody-selectable filamentous fd phage vectors: affinity purification of target genes | Q36434701 |
| | Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | Q36459907 |
| | Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells | Q36539682 |
| | Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease | Q36677345 |
| | Creation of mice expressing human antibody light chains by introduction of a yeast artificial chromosome containing the core region of the human immunoglobulin kappa locus. | Q36705203 |
| | Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome | Q36766593 |
| | A Therapeutic Antibody for Cancer, Derived from Single Human B Cells | Q36913660 |
| | Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak | Q36988908 |
| | Fc-receptors as regulators of immunity. | Q36991445 |
| | The growth and potential of human antiviral monoclonal antibody therapeutics. | Q37027166 |
| | A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve | Q37263716 |
| | Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies | Q37563516 |
| | Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains | Q37576261 |
| | Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors | Q37593886 |
| | Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. | Q45975157 |
| | Antibody affinity maturation by chain shuffling. | Q46011567 |
| | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. | Q46438521 |
| | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 |
| | Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs | Q46643016 |
| | Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice | Q46760824 |
| | Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens | Q47233474 |
| | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray | Q47548101 |
| | Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells. | Q47645234 |
| | Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design | Q47768845 |
| | An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 |
| | Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning | Q48074262 |
| | Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity. | Q48104138 |
| | Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia | Q48191947 |
| | Calcitonin-gene-related peptide pathway mAbs and migraine prevention. | Q49025770 |
| | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | Q49029195 |
| | Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation | Q49361412 |
| | Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia | Q49553520 |
| | Cancer stem cells revisited | Q49557760 |
| | Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona | Q49952575 |
| | Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease | Q50057782 |
| | Analyzing the "degree of humanness" of antibody sequences. | Q51022916 |
| | Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. | Q51151747 |
| | A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action | Q37598513 |
| | Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus | Q37621643 |
| | Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice | Q37702078 |
| | The safety and side effects of monoclonal antibodies | Q37715703 |
| | Humanisation of monoclonal antibodies for therapy | Q37806135 |
| | Molecular engineering of antibodies for therapeutic and diagnostic purposes | Q38017581 |
| | Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody | Q38206839 |
| | The therapeutic monoclonal antibody market | Q38296275 |
| | Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles | Q38356112 |
| | Nivolumab: targeting PD-1 to bolster antitumor immunity | Q38387311 |
| | Chimeric antigen receptor T-cell therapies for lymphoma | Q38600697 |
| | Monoclonal antibodies: technologies for early discovery and engineering | Q38633596 |
| | Single-cell RNA sequencing to explore immune cell heterogeneity | Q38645486 |
| | Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis | Q38673099 |
| | Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. | Q38718049 |
| | Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. | Q38826507 |
| | Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer | Q38851210 |
| | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 |
| | Strategies and challenges for the next generation of antibody-drug conjugates | Q39182945 |
| | Ramucirumab in the treatment of non-small cell lung cancer. | Q39232340 |
| | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. | Q39361301 |
| | The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. | Q39828671 |
| | Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering | Q39922718 |
| | Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody | Q39966889 |
| | Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells | Q40067406 |
| | Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions | Q40095659 |
| | Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. | Q40098189 |
| | From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice | Q40166479 |
| | Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial | Q40230845 |
| | Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 |
| | IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma | Q40645948 |
| | Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nephropathia epidemica: a novel method using antigen-coated magnetic beads for specific B cell isolation | Q40716482 |
| | Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections | Q40874465 |
| | Identification and characterization of a novel scFv recognizing human and mouse CD133. | Q41129253 |
| | Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. | Q41228724 |
| | Phage display-derived human antibodies in clinical development and therapy | Q41416393 |
| | Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. | Q41658299 |
| | Modulating IgG effector function by Fc glycan engineering. | Q41677985 |
| | Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. | Q43646588 |
| | The humanness of macaque antibody sequences | Q44429848 |
| | Dupilumab in persistent asthma with elevated eosinophil levels | Q44480181 |
| | High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries | Q45325444 |
| | Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein | Q45752849 |
| | Emicizumab Prophylaxis in Hemophilia A with Inhibitors | Q45869610 |
| | Single cell sorting and cloning. | Q34032191 |
| | B cell development in mice that lack one or both immunoglobulin kappa light chain genes. | Q34044647 |
| | Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial | Q34092311 |
| | The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions | Q34110768 |
| | Somatic immunoglobulin hypermutation | Q34116350 |
| | Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | Q34156748 |
| | Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer | Q34239801 |
| | A repertoire of monoclonal antibodies with human heavy chains from transgenic mice | Q34301539 |
| | Antibody therapeutics in cancer. | Q34370627 |
| | Design of humanized antibodies: from anti-Tac to Zenapax | Q34413412 |
| | In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates | Q34421845 |
| | IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma | Q34440364 |
| | Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis. | Q34468474 |
| | A microengraving method for rapid selection of single cells producing antigen-specific antibodies | Q34525792 |
| | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 |
| | Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb | Q34563596 |
| | Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis | Q34576320 |
| | Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones | Q34593818 |
| | A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. | Q34617336 |
| | Selection and in vitro characterization of human CD44v6-binding antibody fragments. | Q34668788 |
| | Monoclonal antibody humanness score and its applications | Q34798313 |
| | Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen | Q34953172 |
| | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 |
| | The influence of antibody fragment format on phage display based affinity maturation of IgG. | Q35050036 |
| | A highly functional synthetic phage display library containing over 40 billion human antibody clones | Q35192223 |
| | The role of phage display in therapeutic antibody discovery | Q35227681 |
| | A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. | Q51564288 |
| | Cell-microarray analysis of antigen-specific B-cells: single cell analysis of antigen receptor expression and specificity. | Q51577805 |
| | Progress and challenges towards targeted delivery of cancer therapeutics. | Q52590993 |
| | CAR T cell immunotherapy for human cancer. | Q52641908 |
| | Avelumab for the treatment of urothelial cancer. | Q52655736 |
| | A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. | Q52659466 |
| | Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. | Q52850198 |
| | IMGT, the International ImMunoGeneTics Information System. | Q53152495 |
| | Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients. | Q53296605 |
| | Guselkumab for the Treatment of Psoriasis. | Q54268464 |
| | Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. | Q54269757 |
| | A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. | Q54382839 |
| | Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. | Q54407475 |
| | Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. | Q55279671 |
| | Next generation immune-checkpoints for cancer therapy. | Q55383705 |
| | Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now? | Q55436995 |
| | Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia | Q56355787 |
| | Immunodominance of the VH1-46 Antibody Gene Segment in the Primary Repertoire of Human Rotavirus-Specific B Cells Is Reduced in the Memory Compartment through Somatic Mutation of Nondominant Clones | Q56480791 |
| | Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study | Q57752112 |
| | Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model | Q58569620 |
| | Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis | Q58992083 |
| | Cryo-EM structure of the active, G-protein complexed, human CGRP receptor | Q59054344 |
| | Antigen-specific human antibodies from mice comprising four distinct genetic modifications | Q59076205 |
| | Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 | Q59354501 |
| | Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis | Q59789344 |
| | Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies | Q63246138 |
| | Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies | Q64042096 |
| | Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma | Q64071263 |
| | Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs | Q64108799 |
| | Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans | Q64360021 |
| | Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. | Q64928870 |
| | Engineering antibodies for therapy | Q67482024 |
| | Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain | Q71397837 |
| | Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6 | Q72792651 |
| | Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus | Q72871432 |
| | Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection | Q73207762 |
| | A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis | Q78472012 |
| | Immunogenicity, efficacy and adverse events of adalimumab in RA patients | Q79151701 |
| | Ustekinumab for chronic plaque psoriasis | Q81295694 |
| | Mice with a human touch | Q81408130 |
| | Denosumab (AMG 162), a Fully Human Monoclonal Antibody Against RANK Ligand Activity | Q81652269 |
| | Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease | Q81763008 |
| | Hereditary angioedema: new findings concerning symptoms, affected organs, and course | Q82612998 |
| | Belimumab | Q84007453 |
| | Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function | Q84434660 |
| | Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study | Q87056653 |
| | CGRP as the target of new migraine therapies - successful translation from bench to clinic | Q88462429 |
| | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | Q88973620 |
| | The Increasingly Human and Profitable Monoclonal Antibody Market | Q89265567 |
| | In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin | Q30769483 |
| | Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy | Q30790872 |
| | Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display | Q30820969 |
| | Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides | Q30836158 |
| | A comparison of hydraulic and laser capture microdissection methods for collection of single B cells, PCR, and sequencing of antibody VDJ. | Q31080414 |
| | Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity | Q31153818 |
| | Recombinant human monoclonal antibodies to Ebola virus | Q31905799 |
| | Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library | Q32060783 |
| | Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens | Q32062847 |
| | Antibodies from phage antibody libraries | Q33204934 |
| | Selecting and screening recombinant antibody libraries | Q33223036 |
| | Manufacturing immunity to disease in a test tube: the magic bullet realized | Q33264333 |
| | Single lymphocyte analysis with a microwell array chip | Q33304504 |
| | Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies | Q33328393 |
| | Making antibody fragments using phage display libraries | Q33392386 |
| | A method for identification of HIV gp140 binding memory B cells in human blood | Q33394829 |
| | A surface expression vector for antibody screening | Q33402114 |
| | Affinity maturation by phage display | Q33413793 |
| | Phage-display selection on tumor histological specimens with laser capture microdissection | Q33470770 |
| | A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. | Q33492227 |
| | Abciximab. An updated review of its use in ischaemic heart disease | Q33504164 |
| | Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells | Q33620053 |
| | Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 |
| | Screening individual hybridomas by microengraving to discover monoclonal antibodies | Q33667656 |
| | Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells | Q33786889 |
| | Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery | Q33816457 |
| | Identifying blood-brain-barrier selective single-chain antibody fragments | Q33816474 |
| | Beyond natural antibodies: the power of in vitro display technologies | Q33841864 |
| | Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study | Q33880042 |
| | Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 |
| | The promise and challenge of high-throughput sequencing of the antibody repertoire. | Q33962293 |
| | Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays | Q33998313 |
| | Phage antibodies: filamentous phage displaying antibody variable domains | Q34031345 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P921 | main subject | neoplasm | Q1216998 |
| | metabolic disease | Q2351083 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2020-01-02 | |
| P1433 | published in | Journal of Biomedical Science | Q15759332 |
| P1476 | title | Development of therapeutic antibodies for the treatment of diseases | |
| P478 | volume | 27 | |